CorMedix enters the final stretch before its November 11 earnings with a rare combination: short interest still running at a structurally elevated level, yet shorts themselves are quietly trimming, even as options traders push defensive positioning to a near-52-week extreme.
The short-side picture is a study in gradual retreat. Twenty percent of the free float is still short — a level that puts CRMD firmly in the top tier of heavily shorted small-cap pharma names. But the direction of travel has shifted. Short interest has fallen roughly 1.7% over the past week and about 2.2% over the past month, with the daily share count declining steadily from a peak above 16.6 million in early September to just under 15.9 million now. Borrow availability has loosened slightly too, running at 38% — tight by broad market standards but meaningfully easier than the sub-15% readings seen in mid-August, when the lending pool was close to fully consumed. Cost to borrow remains low at 0.86%, barely changed from recent weeks, suggesting there is no premium being paid to maintain these short positions. The ORTEX short score sits at 82.9, near the top of its recent range — reflecting the structurally heavy positioning — but the day-to-day trend in actual share counts points toward modest short covering rather than new pressure building.
Options positioning tells a different story. Traders are more defensively positioned than at any other point in the past year. The put/call ratio has jumped to 0.95, nearly three standard deviations above its 20-day average of 0.80 — the highest reading since at least August 2025 and essentially at the 52-week peak of 0.95 recorded on September 21. That is a sharp break from where the ratio was trading through most of August and early September, when it hovered in the 0.77–0.81 range. The shift into puts is notable precisely because short interest is easing: it suggests some participants are rotating from outright short positions into options to maintain downside exposure, or that a separate group of holders is hedging long positions ahead of the November print.
The Street remains constructive, but the setup reflects a stock still trading at a significant discount to targets. Oppenheimer initiated coverage this morning with an Outperform rating and a $15 target — the most recent bellwether action and a meaningful endorsement given the stock's current price near $7.78. RBC Capital raised its target to $14 following the August earnings beat, then trimmed it back to $13 mid-summer before restoring it, reflecting the choppy path around the Melinta acquisition integration. The mean target across three covering analysts sits at $15.33, implying roughly 97% upside from current levels. The bull case centers on DefenCath gaining broader dialysis penetration alongside Melinta's additional revenue streams. Bears point to single-product concentration risk and execution uncertainty around integrating an acquired business. Valuation multiples are modest — a trailing P/E just under 15 and an EV/EBITDA around 5.1 — though EPS momentum factor scores rank in the bottom decile of the universe, a reminder that near-term earnings revisions are working against the stock.
Institutional ownership reinforces the concentrated nature of this name. BlackRock holds just over 8% of shares as of August 31, adding roughly 357,000 shares in the most recent disclosed period. Deep Track Capital, a specialist healthcare fund, holds a nearly identical 8% stake — unchanged from the prior filing but up from 6.3% when they first disclosed. The Vanguard Group filed a 13G/A in March showing a position that has effectively gone to zero, an unusual move that is worth noting. With three holders each controlling close to 6% or more, a relatively thin float, and 20% of what remains sold short, any material shift in any of these positions amplifies price moves in either direction. The 13D/G register carries no activist filer — all large holders are passive — though stakes are as-last-disclosed and positions below the 5% threshold can exit without further notification.
The August earnings reaction is the most relevant historical data point on hand. The stock rose 6.2% on the day of the August 13 report and extended the move to nearly 16% over the following five trading days — a meaningful post-earnings pop in a name where the short base is substantial. The next event is November 11. Between now and then, the tension worth watching is whether the options-driven defensiveness is justified by fundamental developments or proves to be overcautious, and how the short base responds as that date approaches.
See the live data behind this article on ORTEX.
Open CRMD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
